| Aug 9 |
4D Molecular Therapeutics Fabry candidate clinical hold lifted
|
| Aug 9 |
4D Molecular Therapeutics GAAP EPS of -$0.63 beats by $0.06, revenue of $0.01M misses by $0.68M
|
| Aug 8 |
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 8 |
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
|
| Aug 5 |
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
|
| Jul 20 |
4D Molecular Therapeutics: Yesterday's Wet-AMD Data Given Thumbs Down By Market
|
| Jul 19 |
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
|
| Jul 18 |
Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights
|
| Jul 17 |
4D Molecular Therapeutics, Inc. (FDMT) Special Call Transcript
|
| Jul 17 |
4D Molecular Therapeutics falls 30% following phase 2 wet AMD candidate data
|
